AUR-AFR4-TTM1-A-1-1-R-A743-41
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.410
- PANCREAS_BETA_CELLS+0.380
- SPERMATOGENESIS+0.340
- MYC_TARGETS_V2+0.310
- E2F_TARGETS+0.290
- OXIDATIVE_PHOSPHORYLATION+0.290
- G2M_CHECKPOINT+0.240
- MTORC1_SIGNALING+0.240
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.160
- KRAS_SIGNALING_DN+0.150
Top 10 suppressed
- ANGIOGENESIS-0.510
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- UV_RESPONSE_DN-0.370
- TNFA_SIGNALING_VIA_NFKB-0.360
- IL6_JAK_STAT3_SIGNALING-0.350
- TGF_BETA_SIGNALING-0.340
- APOPTOSIS-0.320
- COAGULATION-0.320
- ANDROGEN_RESPONSE-0.270
- APICAL_JUNCTION-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-66-2754-01A-01R-0980-07 | — | cohortA3 | 0.859 |
| 2 | TCGA-33-4582-01A-01R-1443-07 | — | cohortSQ2 | 0.848 |
| 3 | SRR1313148 | — | E | 0.845 |
| 4 | SRR25617827 | — | E | 0.841 |
| 5 | SRR4195684 | — | — | 0.841 |
| 6 | TCGA-HD-A634-01A-11R-A28V-07 | — | — | 0.840 |
| 7 | BS_YETBN0RQ | medulloblastoma | — | 0.840 |
| 8 | SRR650205 | — | — | 0.839 |
| 9 | SRR8518130 | — | E | 0.838 |
| 10 | SRR12696795 | — | — | 0.838 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.380 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.310 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.110 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.070 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.020 | Idelalisib | — uncovered |